隨著編輯委員會(huì)的修訂，白血病研究正在進(jìn)一步發(fā)展其目標(biāo)，即為所有參與白血病和其他血液惡性腫瘤的基礎(chǔ)研究和應(yīng)用臨床研究的衛(wèi)生保健專(zhuān)業(yè)人員提供全面和最新的信息。編輯鼓勵(lì)提交有關(guān)正常和白血病造血、生物化學(xué)、細(xì)胞生物學(xué)、免疫學(xué)、分子生物學(xué)以及流行病學(xué)和臨床研究的文章。特別地，主要的興趣將是文章，包括應(yīng)用癌基因，生長(zhǎng)因子，細(xì)胞標(biāo)記物，細(xì)胞周期和分化劑，新療法和臨床試驗(yàn)在急性和慢性白血病以及骨髓增生異常綜合征。此外，我們還征集了一些關(guān)于大范圍腫瘤患者在接受高劑量治療并嘗試治療后骨髓或干細(xì)胞重建迅速增加的特點(diǎn)的文章。更多信息請(qǐng)聯(lián)系骨髓增生異常綜合征基金會(huì)http://www.mds-found.org/

With a revised editorial board in place, Leukemia Research is further developing its goal of bringing comprehensive and current information to all health care professionals involved in basic research and applied clinical research in both leukemias and other hematologic malignancies. The editors encourage the submission of articles relevant to normal and leukemic hemopoiesis, biochemistry, cell biology, immunology, molecular biology as well as epidemiologic and clinical studies. Specifically, of major interest will be articles that encompass the application of oncogenes, growth factors, cell markers, cell cycle and differentiation agents, novel therapeutics and clinical trials in both the acute and chronic leukemias as well as the myelodysplastic syndromes. In addition we solicit selected articles on the rapidly increasing specialty of marrow or stem cell reconstitution after high dose therapy with curative attempt in patients with a wide range of neoplasms.For more information contact the Myelodysplastic Syndromes Foundation at http://www.mds-foundation.org/